The IRAK4 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population in which the human IRAK4 gene has been disrupted in the A-549 host cell background. This polyclonal pool reflects a heterogeneous collection of gene-edited alleles, offering a genetically mixed loss-of-function model free from clonal selection artifacts. The cells provide a ready-to-use system for interrogating IRAK4-dependent signal transduction in an epithelial context.
The A-549 cell line originates from human lung carcinoma and displays characteristics of type II alveolar pneumocytes, including the ability to form polarized monolayers and produce surfactant. These cells serve as a well-established in vitro model of the distal lung epithelium, retaining key innate immune signaling machinery. Their epithelial identity makes them particularly suitable for investigating host defense and inflammatory responses within the pulmonary environment.
IRAK4 encodes a critical serine/threonine kinase activated downstream of MyD88 following TLR and IL-1R stimulation. It phosphorylates IRAK1 and IRAK2, leading to TRAF6 oligomerization and subsequent activation of the TAK1 kinase complex. TAK1 triggers both the IKK complex, driving NF-??B nuclear translocation, and MAP kinases (ERK, JNK, p38), which activate AP-1. These transcription factors induce pro-inflammatory cytokines such as TNF, IL-6, and IL-8. IRAK4 also interacts with adaptors including MyD88, Tollip, and Pellino-1, positioning it as a central node in innate immune signal amplification.
In A-549 cells, IRAK4 mediates epithelial inflammatory cytokine secretion in response to TLR ligands (e.g., LPS, CpG) and IL-1 family cytokines. Disrupting IRAK4 permits dissection of the epithelial contribution to pulmonary inflammation without immune cell interference. This model is instrumental for exploring IRAK4??s role in conditions like COPD, asthma, and lung cancer, where aberrant NF-??B and MAPK signaling drives pathology. Additionally, given the cancer origin of A-549, this model can be used to study tumor-intrinsic inflammatory signaling.
Typical applications include western blotting for phospho-IRAK1, phospho-p65, and phospho-MAPKs; RT-qPCR and RNA-seq for cytokine transcript profiling; and ELISA for secreted IL-6, IL-8, and TNF. NF-??B reporter assays and co-immunoprecipitation of MyD88?CIRAK4 complexes further enable pathway analysis. This knockout model supports innate immunity research, inflammatory disease modeling, and drug target validation. For inquiries, please contact Ascent Research.
